Innovative bio-pharmaceutical development company
Innovative bio-pharmaceutical company seeking $12 million of equity. Developing a new and novel pain killer that has been cleared to enter Phase 2 clinical testing. Compound is from a new class of drugs that could be an alternative and potential replacement for classical opioids, which are highly addictive and have many side effects.
- Based on natural pain killers produced by the human body
- Trials have shown this drug to be three to four times more potent than morphine – reduced recovery times, reduced side-effects and substantially reduced abuse potential
- According to the National Institute of Drug Abuse (NIDA), approximately 47,000 people in the US died in 2018 from opioid addiction
- Massive global market for opioids of about $25 billion
- Over $20 million invested previously in the company
- Led by team of experienced drug industry professionals and renowned clinical and scientific advisors